Investigation launched into ADMA Biologics for alleged channel-stuffing to boost ASCENIV sales.

Berger Montague law firm is investigating ADMA Biologics' Board of Directors for potential breaches of fiduciary duty, focusing on allegations that the company engaged in channel-stuffing to inflate revenue despite declining demand for its main product, ASCENIV. This investigation could impact shareholders and the company's reputation. Investors interested in the case can contact Berger Montague for more information. ADMA is a biopharmaceutical company specializing in treatments for immune deficiencies and infectious diseases.